Literature DB >> 9397417

Protein metabolism in acute renal failure.

W Druml1.   

Abstract

The hallmark of metabolic alterations in acute renal failure (ARF) is accelerated protein breakdown which, unfortunately, cannot be suppressed effectively by provision of exogenous nutritional substrates. Causes of excessive protein catabolism are manifold and present a combination of unspecific mechanisms induced by the acute disease process and underlying illness or associated complications, effects induced by the acute loss of renal function and, finally, the type and intensity of renal replacement therapy. Specific uremic toxic effects, insulin resistance, hormonal derangements, metabolic acidosis, circulating proteases, inflammatory mediators, and dialysis-related losses of nutritional substrates all contribute to the activation of protein degradation. Metabolism in ARF is also affected by an impairment of the multiple metabolic and endocrine functions of the kidney. Various amino acids are synthesized or interconverted by the kidneys and may become conditionally indispensable. The kidney is also an important organ in the degradation of peptides, such as peptide hormones. As a consequence of these metabolic aberrations, imbalances in amino acid pools in plasma and in the intracellular compartment occur in ARF and elimination and utilization of infused amino acids is altered. Protein or amino acids requirements are influenced more by the nature of the illness causing ARF, by the extent of hypercatabolism, by associated complications, and by the type and frequency of renal replacement therapy than by renal dysfunction per se. In noncatabolic patients, an intake of 1 g/kg body weight per day may be sufficient, while in critically ill hypercatabolic patients undergoing continuous renal replacement therapy, 1.5 g amino acids/kg body weight per day should be provided to minimize nitrogen losses. For the future, we need to identify safe methods to control the accelerated catabolism in order to improve the efficiency of nutritional interventions in patients with ARF.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9397417     DOI: 10.1159/000057350

Source DB:  PubMed          Journal:  Miner Electrolyte Metab        ISSN: 0378-0392


  5 in total

1.  Composition of human breast milk in acute kidney injury.

Authors:  Adam Chruscicki; Alexander Ross Morton; Ayub Akbari; Christine Anne White
Journal:  Obstet Med       Date:  2017-01-29

2.  Continuous renal replacement therapy amino acid, trace metal and folate clearance in critically ill children.

Authors:  Michael Zappitelli; Marisa Juarez; L Castillo; Jorge Coss-Bu; Stuart L Goldstein
Journal:  Intensive Care Med       Date:  2009-01-29       Impact factor: 17.440

3.  Antiglucocorticoid RU38486 reduces net protein catabolism in experimental acute renal failure.

Authors:  Adrian Mondry
Journal:  BMC Nephrol       Date:  2005-02-17       Impact factor: 2.388

4.  Calorie intake and patient outcomes in severe acute kidney injury: findings from The Randomized Evaluation of Normal vs. Augmented Level of Replacement Therapy (RENAL) study trial.

Authors:  Rinaldo Bellomo; Alan Cass; Louise Cole; Simon Finfer; Martin Gallagher; Joanne Lee; Serigne Lo; Colin McArthur; Shay McGuinness; John Myburgh; Robyn Norton; Carlos Scheinkestel; Steve Su
Journal:  Crit Care       Date:  2014-03-14       Impact factor: 9.097

Review 5.  Glutamine: an obligatory parenteral nutrition substrate in critical care therapy.

Authors:  Peter Stehle; Katharina S Kuhn
Journal:  Biomed Res Int       Date:  2015-10-01       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.